| __timestamp | Amphastar Pharmaceuticals, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 44820000 |
| Thursday, January 1, 2015 | 46974000 | 82080000 |
| Friday, January 1, 2016 | 47298000 | 97130000 |
| Sunday, January 1, 2017 | 50918000 | 121271000 |
| Monday, January 1, 2018 | 58044000 | 153548000 |
| Tuesday, January 1, 2019 | 63109000 | 202541000 |
| Wednesday, January 1, 2020 | 65157000 | 245164000 |
| Friday, January 1, 2021 | 68920000 | 285773000 |
| Saturday, January 1, 2022 | 66592000 | 325998000 |
| Sunday, January 1, 2023 | 80393000 | 332540000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Over the past decade, PTC Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, PTC Therapeutics experienced a staggering 642% increase in SG&A expenses, peaking in 2023. In contrast, Amphastar Pharmaceuticals saw a more modest 99% rise over the same period. This disparity highlights PTC's aggressive expansion and investment strategies compared to Amphastar's more conservative approach. Notably, in 2023, PTC's SG&A expenses were nearly four times higher than Amphastar's, reflecting its commitment to growth and market penetration. As the pharmaceutical landscape continues to shift, these financial insights offer a glimpse into the strategic priorities of these industry players.
AbbVie Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Incyte Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Viatris Inc. vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and PTC Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cytokinetics, Incorporated or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Amphastar Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Vericel Corporation
Who Optimizes SG&A Costs Better? PTC Therapeutics, Inc. or HUTCHMED (China) Limited
ImmunityBio, Inc. and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Iovance Biotherapeutics, Inc. and Amphastar Pharmaceuticals, Inc.